Recent Updates
Recently added Catalysts
LXRX

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Friday, December 20, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Price reaction · baseline $0.7236 (2024-12-19 close) · hit after-hours · clean, no other LXRX news in the window
day 0 close · peak
-1.2%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus

Full Press Release Details

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin).
ShareAdd on Google
Tags: LXRX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Dec 20, 2024

Biotech snapshot

Cash runway
$191M liquidity · $3M/mo burn
~61 mo
Minimal dilution risk
Lead asset
SotagliflozinPhase 3
Type 1 Diabetes Mellitus →

Catalyst track record

+111%
best trade around LXRX's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for LXRX.

See every catalyst's timing & PoA →